Mr. Hugh MacNaught reports

VENTRIPOINT HIRES ERG TO PROVIDE INVESTOR RELATIONS SERVICES

Ventripoint Diagnostics Ltd. has entered into an investor relations (IR) agreement with Empire Relations Group Inc. (ERG). The IR agreement is for an initial term from July 25, 2024, to Dec. 8, 2024, with a company option to extend the agreement for an additional three months.

ERG specializes in outreach to professional investors, who are interested in companies with novel medical products, which will change health care, and Ventripoint meets all of ERG's criteria with its disruptive technology to better visualize the heart using routine ultrasound exams.

Pursuant to the IR agreement, Empire will be paid a fee of $18,000 (U.S.) for the initial term of the agreement and $18,000 (U.S.) in advance for the extension period.

The IR agreement is subject to the approval of the TSX Venture Exchange.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide its future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.